Kezar Life Sciences Ownership 2024 | Who Owns Kezar Life Sciences Now?
Institutional Ownership
61.66%
Insider Ownership
14.84%
Retail Ownership
23.50%
Institutional Holders
85.00
Kezar Life Sciences Institutional Shareholders
Institutional Shareholders by % of Total Shares
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| SUVRETTA CAPITAL MANAGEMENT, LLC | 9.88% | 0.24% | 7,167,591 | - | - | 6,462,300 | Mar 31, 2024 |
| AVIDITY PARTNERS MANAGEMENT LP | 6.93% | 0.15% | 5,026,000 | 546 | 0.01% | 4,531,442 | Mar 31, 2024 |
| BLACKROCK INC. | 6.36% | 0.00% | 4,616,988 | -200,278 | -4.16% | 4,162,677 | Mar 31, 2024 |
| VANGUARD GROUP INC | 4.26% | 0.00% | 3,094,224 | 30,740 | 1.00% | 2,789,753 | Mar 31, 2024 |
| SPHERA FUNDS MANAGEMENT LTD. | 2.83% | 0.26% | 2,051,676 | - | - | 1,849,791 | Mar 31, 2024 |
| ORBIMED ADVISORS LLC | 2.66% | 0.03% | 1,927,000 | - | - | 1,737,383 | Mar 31, 2024 |
| ACADIAN ASSET MANAGEMENT LLC | 2.47% | 0.01% | 1,790,838 | 534,203 | 42.51% | 1,613,000 | Mar 31, 2024 |
| AFFINITY ASSET ADVISORS, LLC | 2.43% | 0.20% | 1,761,778 | 1,761,778 | 100.00% | 1,588,419 | Mar 31, 2024 |
| GEODE CAPITAL MANAGEMENT, LLC | 1.89% | 0.00% | 1,373,689 | 19,041 | 1.41% | 1,238,643 | Mar 31, 2024 |
| RENAISSANCE TECHNOLOGIES LLC | 1.84% | 0.00% | 1,338,074 | 46,155 | 3.57% | 1,206,000 | Mar 31, 2024 |
| TWO SIGMA INVESTMENTS, LP | 1.79% | 0.00% | 1,302,254 | 86,007 | 7.07% | 1,174,112 | Mar 31, 2024 |
| TWO SIGMA ADVISERS, LP | 1.70% | 0.00% | 1,231,800 | -90,500 | -6.84% | 1,110,591 | Mar 31, 2024 |
| STATE STREET CORP | 1.55% | - | 1,123,774 | 7,722 | 0.69% | 1,013,195 | Mar 31, 2024 |
| PROSIGHT MANAGEMENT, LP | 1.33% | 0.24% | 963,598 | -2,401,735 | -71.37% | 868,780 | Mar 31, 2024 |
| IKARIAN CAPITAL, LLC | 1.20% | 0.09% | 868,992 | 15,601 | 1.83% | 783,484 | Mar 31, 2024 |
| QIMING U.S. VENTURES MANAGEMENT, LLC | 1.14% | 0.83% | 828,711 | - | - | 747,166 | Mar 31, 2024 |
| MILLENNIUM MANAGEMENT LLC | 1.13% | 0.00% | 816,973 | -2,110,590 | -72.09% | 736,583 | Mar 31, 2024 |
| ACUITAS INVESTMENTS, LLC | 0.95% | 0.31% | 690,829 | 690,829 | 100.00% | 622,851 | Mar 31, 2024 |
| TANG CAPITAL MANAGEMENT LLC | 0.95% | 0.06% | 688,943 | 382,278 | 124.66% | 621,151 | Mar 31, 2024 |
| NORTHERN TRUST CORP | 0.71% | 0.00% | 515,363 | -28,103 | -5.17% | 464,651 | Mar 31, 2024 |
Kezar Life Sciences's largest institutional shareholder is SUVRETTA CAPITAL MANAGEMENT, LLC, holding 9.88% of the company's total share outstanding, currently valued at $6.46M. The top 10 institutional shareholders own together 41.55% of the company.
Institutional Shareholders by % of Total Assets
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| QIMING U.S. VENTURES MANAGEMENT, LLC | 1.14% | 0.83% | 828,711 | - | - | 747,166 | Mar 31, 2024 |
| ACUITAS INVESTMENTS, LLC | 0.95% | 0.31% | 690,829 | 690,829 | 100.00% | 622,851 | Mar 31, 2024 |
| SPHERA FUNDS MANAGEMENT LTD. | 2.83% | 0.26% | 2,051,676 | - | - | 1,849,791 | Mar 31, 2024 |
| PROSIGHT MANAGEMENT, LP | 1.33% | 0.24% | 963,598 | -2,401,735 | -71.37% | 868,780 | Mar 31, 2024 |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 9.88% | 0.24% | 7,167,591 | - | - | 6,462,300 | Mar 31, 2024 |
| AFFINITY ASSET ADVISORS, LLC | 2.43% | 0.20% | 1,761,778 | 1,761,778 | 100.00% | 1,588,419 | Mar 31, 2024 |
| AVIDITY PARTNERS MANAGEMENT LP | 6.93% | 0.15% | 5,026,000 | 546 | 0.01% | 4,531,442 | Mar 31, 2024 |
| IKARIAN CAPITAL, LLC | 1.20% | 0.09% | 868,992 | 15,601 | 1.83% | 783,484 | Mar 31, 2024 |
| TANG CAPITAL MANAGEMENT LLC | 0.95% | 0.06% | 688,943 | 382,278 | 124.66% | 621,151 | Mar 31, 2024 |
| ADAR1 CAPITAL MANAGEMENT, LLC | 0.33% | 0.05% | 236,623 | 236,623 | 100.00% | 213,339 | Mar 31, 2024 |
| ORBIMED ADVISORS LLC | 2.66% | 0.03% | 1,927,000 | - | - | 1,737,383 | Mar 31, 2024 |
| GSA CAPITAL PARTNERS LLP | 0.39% | 0.02% | 282,595 | 22,188 | 8.52% | 255,000 | Mar 31, 2024 |
| MARQUETTE ASSET MANAGEMENT, LLC | 0.17% | 0.02% | 126,095 | 126,095 | 100.00% | 113,688 | Mar 31, 2024 |
| IRONWOOD INVESTMENT MANAGEMENT LLC | 0.04% | 0.01% | 28,012 | 2,864 | 11.39% | 25,256 | Mar 31, 2024 |
| ACADIAN ASSET MANAGEMENT LLC | 2.47% | 0.01% | 1,790,838 | 534,203 | 42.51% | 1,613,000 | Mar 31, 2024 |
| RETIREMENT CAPITAL STRATEGIES | 0.02% | 0.01% | 15,000 | - | - | 13,524 | Mar 31, 2024 |
| OCCUDO QUANTITATIVE STRATEGIES LP | 0.04% | 0.01% | 31,769 | -2,525 | -7.36% | 28,643 | Mar 31, 2024 |
| PRELUDE CAPITAL MANAGEMENT, LLC | 0.14% | 0.00% | 100,801 | 100,801 | 100.00% | 90,882 | Mar 31, 2024 |
| ATOM INVESTORS LP | 0.03% | 0.00% | 25,149 | 25,149 | 100.00% | 22,674 | Mar 31, 2024 |
| FIDELIS CAPITAL PARTNERS, LLC | 0.04% | 0.00% | 27,266 | 27,266 | 100.00% | 24,583 | Mar 31, 2024 |
The largest Kezar Life Sciences shareholder by % of total assets is QIMING U.S. VENTURES MANAGEMENT, LLC. The company owns 828.71K shares of Kezar Life Sciences (KZR), representing 0.83% of its total assets.
Institutional Buyers
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| AFFINITY ASSET ADVISORS, LLC | 2.43% | 0.20% | 1,761,778 | 1,761,778 | 100.00% | 1,588,419 | Mar 31, 2024 |
| ACUITAS INVESTMENTS, LLC | 0.95% | 0.31% | 690,829 | 690,829 | 100.00% | 622,851 | Mar 31, 2024 |
| ACADIAN ASSET MANAGEMENT LLC | 2.47% | 0.01% | 1,790,838 | 534,203 | 42.51% | 1,613,000 | Mar 31, 2024 |
| TANG CAPITAL MANAGEMENT LLC | 0.95% | 0.06% | 688,943 | 382,278 | 124.66% | 621,151 | Mar 31, 2024 |
| ADAR1 CAPITAL MANAGEMENT, LLC | 0.33% | 0.05% | 236,623 | 236,623 | 100.00% | 213,339 | Mar 31, 2024 |
| PANAGORA ASSET MANAGEMENT INC | 0.32% | 0.00% | 233,206 | 149,119 | 177.34% | 210,259 | Mar 31, 2024 |
| CITADEL ADVISORS LLC | 0.70% | 0.00% | 509,564 | 144,235 | 39.48% | 459,423 | Mar 31, 2024 |
| MARQUETTE ASSET MANAGEMENT, LLC | 0.17% | 0.02% | 126,095 | 126,095 | 100.00% | 113,688 | Mar 31, 2024 |
| PRELUDE CAPITAL MANAGEMENT, LLC | 0.14% | 0.00% | 100,801 | 100,801 | 100.00% | 90,882 | Mar 31, 2024 |
| TWO SIGMA INVESTMENTS, LP | 1.79% | 0.00% | 1,302,254 | 86,007 | 7.07% | 1,174,112 | Mar 31, 2024 |
| BNP PARIBAS ARBITRAGE, SNC | 0.38% | 0.00% | 273,430 | 71,543 | 35.44% | 246,524 | Mar 31, 2024 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 0.07% | - | 53,316 | 53,316 | 100.00% | 48,070 | Mar 31, 2024 |
| RENAISSANCE TECHNOLOGIES LLC | 1.84% | 0.00% | 1,338,074 | 46,155 | 3.57% | 1,206,000 | Mar 31, 2024 |
| D. E. SHAW & CO., INC. | 0.58% | 0.00% | 419,425 | 42,449 | 11.26% | 378,153 | Mar 31, 2024 |
| VANGUARD GROUP INC | 4.26% | 0.00% | 3,094,224 | 30,740 | 1.00% | 2,789,753 | Mar 31, 2024 |
| FIDELIS CAPITAL PARTNERS, LLC | 0.04% | 0.00% | 27,266 | 27,266 | 100.00% | 24,583 | Mar 31, 2024 |
| MIRAE ASSET GLOBAL INVESTMENTS CO., LTD. | 0.04% | 0.00% | 26,195 | 26,195 | 100.00% | 84,086 | Mar 31, 2024 |
| ATOM INVESTORS LP | 0.03% | 0.00% | 25,149 | 25,149 | 100.00% | 22,674 | Mar 31, 2024 |
| UBS GROUP AG | 0.10% | - | 71,509 | 22,335 | 45.42% | 64,501 | Mar 31, 2024 |
| GSA CAPITAL PARTNERS LLP | 0.39% | 0.02% | 282,595 | 22,188 | 8.52% | 255,000 | Mar 31, 2024 |
As of Mar 31 2024, Kezar Life Sciences's largest institutional buyer is AFFINITY ASSET ADVISORS, LLC. The company purchased 1.76M stocks of KZR, valued at $1.59M.
Institutional Sellers
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| PROSIGHT MANAGEMENT, LP | 1.33% | 0.24% | 963,598 | -2,401,735 | -71.37% | 868,780 | Mar 31, 2024 |
| MILLENNIUM MANAGEMENT LLC | 1.13% | 0.00% | 816,973 | -2,110,590 | -72.09% | 736,583 | Mar 31, 2024 |
| GRANAHAN INVESTMENT MANAGEMENT, LLC | - | - | - | -1,906,175 | -100.00% | - | Mar 31, 2024 |
| JACOBS LEVY EQUITY MANAGEMENT, INC | 0.07% | 0.00% | 53,216 | -917,619 | -94.52% | 47,980 | Mar 31, 2024 |
| ANSON FUNDS MANAGEMENT LP | - | - | - | -611,249 | -100.00% | - | Mar 31, 2024 |
| BLACKROCK INC. | 6.36% | 0.00% | 4,616,988 | -200,278 | -4.16% | 4,162,677 | Mar 31, 2024 |
| SQUAREPOINT OPS LLC | - | - | - | -186,705 | -100.00% | - | Mar 31, 2024 |
| MORGAN STANLEY | 0.14% | - | 101,151 | -158,132 | -60.99% | 91,198 | Mar 31, 2024 |
| HRT FINANCIAL LP | - | - | - | -103,785 | -100.00% | - | Mar 31, 2024 |
| CITADEL ADVISORS LLC | 0.00% | - | 2,600 | -97,800 | -97.41% | 2,344 | Mar 31, 2024 |
| TWO SIGMA ADVISERS, LP | 1.70% | 0.00% | 1,231,800 | -90,500 | -6.84% | 1,110,591 | Mar 31, 2024 |
| PALE FIRE CAPITAL SE | - | - | - | -68,851 | -100.00% | - | Mar 31, 2024 |
| ENGINEERS GATE MANAGER LP | - | - | - | -56,826 | -100.00% | - | Mar 31, 2024 |
| BANK OF AMERICA CORP /DE/ | 0.05% | - | 33,249 | -55,992 | -62.74% | 29,958,000 | Mar 31, 2024 |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | 0.15% | 0.00% | 108,600 | -50,000 | -31.53% | 97,914 | Mar 31, 2024 |
| BARCLAYS PLC | 0.07% | - | 50,118 | -47,919 | -48.88% | 45,000 | Mar 31, 2024 |
| JANE STREET GROUP, LLC | 0.03% | - | 24,569 | -44,863 | -64.61% | 22,151 | Mar 31, 2024 |
| GOLDMAN SACHS GROUP INC | 0.56% | 0.00% | 404,706 | -38,015 | -8.59% | 364,883 | Mar 31, 2024 |
| NORTHERN TRUST CORP | 0.71% | 0.00% | 515,363 | -28,103 | -5.17% | 464,651 | Mar 31, 2024 |
| XTX TOPCO LTD | 0.02% | 0.00% | 16,723 | -27,296 | -62.01% | 15,077 | Mar 31, 2024 |
As of Mar 31 2024, Kezar Life Sciences's biggest institutional seller is PROSIGHT MANAGEMENT, LP. The company sold -2.40M shares of KZR, valued at $868.78K.
Institutional New positions
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| AFFINITY ASSET ADVISORS, LLC | 2.43% | 0.20% | 1,761,778 | 1,761,778 | 100.00% | 1,588,419 | Mar 31, 2024 |
| ACUITAS INVESTMENTS, LLC | 0.95% | 0.31% | 690,829 | 690,829 | 100.00% | 622,851 | Mar 31, 2024 |
| ADAR1 CAPITAL MANAGEMENT, LLC | 0.33% | 0.05% | 236,623 | 236,623 | 100.00% | 213,339 | Mar 31, 2024 |
| MARQUETTE ASSET MANAGEMENT, LLC | 0.17% | 0.02% | 126,095 | 126,095 | 100.00% | 113,688 | Mar 31, 2024 |
| PRELUDE CAPITAL MANAGEMENT, LLC | 0.14% | 0.00% | 100,801 | 100,801 | 100.00% | 90,882 | Mar 31, 2024 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 0.07% | - | 53,316 | 53,316 | 100.00% | 48,070 | Mar 31, 2024 |
| FIDELIS CAPITAL PARTNERS, LLC | 0.04% | 0.00% | 27,266 | 27,266 | 100.00% | 24,583 | Mar 31, 2024 |
| MIRAE ASSET GLOBAL INVESTMENTS CO., LTD. | 0.04% | 0.00% | 26,195 | 26,195 | 100.00% | 84,086 | Mar 31, 2024 |
| ATOM INVESTORS LP | 0.03% | 0.00% | 25,149 | 25,149 | 100.00% | 22,674 | Mar 31, 2024 |
| AQR CAPITAL MANAGEMENT LLC | 0.03% | - | 21,436 | 21,436 | 100.00% | 19,327 | Mar 31, 2024 |
| FIRST BANK & TRUST | 0.02% | 0.00% | 11,739 | 11,739 | 100.00% | 10,584 | Mar 31, 2024 |
| AVANTAX ADVISORY SERVICES, INC. | 0.02% | 0.00% | 11,110 | 11,110 | 100.00% | 10,017 | Mar 31, 2024 |
| CAPITAL ADVISORS, LTD. LLC | 0.00% | 0.00% | 1,608 | 1,608 | 100.00% | 1,000 | Mar 31, 2024 |
| CIBC PRIVATE WEALTH GROUP, LLC | 0.00% | - | 1,000 | 1,000 | 100.00% | 920,000 | Mar 31, 2024 |
| NELSON, VAN DENBURG & CAMPBELL WEALTH MANAGEMENT GROUP, LLC | - | - | 13 | 13 | 100.00% | 11 | Mar 31, 2024 |
Kezar Life Sciences's largest new institutional shareholder by number of shares is AFFINITY ASSET ADVISORS, LLC, purchased 1.76M shares, valued at $1.59M, as of undefined.
Institutional Sold Out
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| GRANAHAN INVESTMENT MANAGEMENT, LLC | - | - | - | -1,906,175 | -100.00% | - | Mar 31, 2024 |
| ANSON FUNDS MANAGEMENT LP | - | - | - | -611,249 | -100.00% | - | Mar 31, 2024 |
| SQUAREPOINT OPS LLC | - | - | - | -186,705 | -100.00% | - | Mar 31, 2024 |
| HRT FINANCIAL LP | - | - | - | -103,785 | -100.00% | - | Mar 31, 2024 |
| PALE FIRE CAPITAL SE | - | - | - | -68,851 | -100.00% | - | Mar 31, 2024 |
| ENGINEERS GATE MANAGER LP | - | - | - | -56,826 | -100.00% | - | Mar 31, 2024 |
| RVW WEALTH, LLC | - | - | - | -23,765 | -100.00% | - | Mar 31, 2024 |
| WEXFORD CAPITAL LP | - | - | - | -23,320 | -100.00% | - | Mar 31, 2024 |
| CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | - | - | - | -11,747 | -100.00% | - | Mar 31, 2024 |
| SIMPLEX TRADING, LLC | - | - | - | -3,430 | -100.00% | - | Mar 31, 2024 |
| QUBE RESEARCH & TECHNOLOGIES LTD | - | - | - | -194 | -100.00% | - | Mar 31, 2024 |
| PNC FINANCIAL SERVICES GROUP, INC. | - | - | - | -187 | -100.00% | - | Mar 31, 2024 |
Kezar Life Sciences's largest sold out institutional shareholder by shares sold is GRANAHAN INVESTMENT MANAGEMENT, LLC, sold -1.91M shares, valued at -, as of undefined.
Kezar Life Sciences Mutual Fund Holders
| Name | % Total Assets | Total Shares | Change Amount | Change % | Date |
|---|---|---|---|---|---|
| Manager Directed Portfolios | 3.66% | 600,079 | - | - | Jan 31, 2024 |
| ALGER FUNDS | 0.19% | 184,619 | - | - | Jan 31, 2024 |
| VICTORY VARIABLE INSURANCE FUNDS | 0.13% | 63,930 | - | - | Dec 31, 2023 |
| VANGUARD VALLEY FORGE FUNDS | 0.08% | 37,867 | - | - | Dec 31, 2023 |
| FIDELITY ADVISOR SERIES VII | 0.08% | 638,139 | - | - | Jan 31, 2024 |
| BRIDGEWAY FUNDS INC | 0.06% | 147,000 | -151,500 | -50.75% | Dec 29, 2023 |
| FORUM FUNDS II | 0.04% | 39,640 | - | - | Jan 31, 2024 |
| VICTORY PORTFOLIOS | 0.03% | 1,013,406 | - | - | Dec 31, 2023 |
| IndexIQ ETF Trust | 0.03% | 71,027 | - | - | Jan 31, 2024 |
| DEUTSCHE DWS INVESTMENTS VIT FUNDS | 0.03% | 11,179 | - | - | Dec 31, 2023 |
| BNY Mellon Strategic Funds, Inc. | 0.02% | 49,096 | - | - | Mar 31, 2024 |
| Humankind Benefit Corp | 0.02% | 456 | - | - | Dec 31, 2023 |
| Federated Hermes MDT Series | 0.02% | 46,568 | - | - | Jan 31, 2024 |
| QUANTITATIVE MASTER SERIES LLC | 0.02% | 122,594 | - | - | Dec 31, 2023 |
| NEW COVENANT FUNDS | 0.01% | 45,653 | - | - | Dec 31, 2023 |
| ETFis Series Trust I | 0.01% | 14,036 | - | - | Jan 31, 2024 |
| FIRST TRUST EXCHANGE-TRADED FUND | 0.01% | 96,456 | - | - | Dec 31, 2023 |
| VANGUARD INDEX FUNDS | 0.01% | 3,407,015 | 764,730 | 28.94% | Dec 31, 2023 |
| TIAA SEPARATE ACCOUNT VA 1 | 0.01% | 1,311 | - | - | Dec 31, 2023 |
| ALPS ETF Trust | 0.00% | 51,347 | - | - | Feb 29, 2024 |
| Nushares ETF Trust | 0.00% | 29,822 | - | - | Jan 31, 2024 |
| FIDELITY CAPITAL TRUST | 0.00% | 40,264 | - | - | Jan 31, 2024 |
| Fidelity Commonwealth Trust II | 0.00% | 23,776 | - | - | Aug 31, 2023 |
| INVESCO EXCHANGE-TRADED FUND TRUST | 0.00% | 266,288 | - | - | Jan 31, 2024 |
| FIDELITY SECURITIES FUND | 0.00% | 237,620 | - | - | Jan 31, 2024 |
| FIDELITY CONCORD STREET TRUST | 0.00% | 506,958 | 48,285 | 10.53% | Feb 29, 2024 |
| GOLDMAN SACHS VARIABLE INSURANCE TRUST | 0.00% | 9,109 | - | - | Dec 31, 2023 |
| Calvert Variable Products, Inc. | 0.00% | 4,127 | - | - | Dec 31, 2023 |
| Direxion Shares ETF Trust | 0.00% | 254,558 | - | - | Jan 31, 2024 |
| VANGUARD INSTITUTIONAL INDEX FUNDS | 0.00% | 43,585 | - | - | Dec 31, 2023 |
| AdvisorShares Trust | 0.00% | 3,601 | - | - | Dec 29, 2023 |
| Principal Exchange-Traded Funds | 0.00% | 14,867 | -2,286 | -13.33% | Mar 31, 2024 |
| FIDELITY ADVISOR SERIES I | 0.00% | 214,500 | - | - | Feb 29, 2024 |
| Voya VARIABLE PORTFOLIOS INC | 0.00% | 29,376 | - | - | Dec 31, 2023 |
| GOLDMAN SACHS TRUST | 0.00% | 142,219 | - | - | Feb 29, 2024 |
| TARGET PORTFOLIO TRUST | 0.00% | 16,400 | - | - | Jan 31, 2024 |
| Meeder Funds | 0.00% | 3,789 | - | - | Mar 31, 2024 |
| GPS Funds I | 0.00% | 3,139 | - | - | Dec 31, 2023 |
| Victory Portfolios II | 0.00% | 35,136 | - | - | Dec 31, 2023 |
| STATE STREET VARIABLE INSURANCE SERIES FUNDS INC | 0.00% | 2,657 | - | - | Dec 31, 2023 |
| SunAmerica Specialty Series | 0.00% | 258 | - | - | Apr 30, 2021 |
| JPMORGAN TRUST II | 0.00% | 464,438 | - | - | Feb 29, 2024 |
| HC CAPITAL TRUST | 0.00% | 14,080 | - | - | Dec 31, 2023 |
| FIDELITY SELECT PORTFOLIOS | 0.00% | 27,452 | - | - | Feb 29, 2024 |
| TIAA-CREF LIFE FUNDS | 0.00% | 1,049 | - | - | Dec 31, 2023 |
| AMERICAN CENTURY ETF TRUST | 0.00% | 40,954 | - | - | Feb 29, 2024 |
| OLD WESTBURY FUNDS INC | 0.00% | 46,803 | - | - | Jan 31, 2024 |
| STATE STREET INSTITUTIONAL INVESTMENT TRUST | 0.00% | 22,030 | - | - | Dec 31, 2023 |
| VARIABLE INSURANCE PRODUCTS FUND II | 0.00% | 2,739 | -1,438 | -34.43% | Dec 31, 2023 |
| T. Rowe Price Index Trust, Inc. | 0.00% | 3,636 | - | - | Feb 29, 2024 |
| RUSSELL INVESTMENT CO | 0.00% | 57,644 | - | - | Jan 31, 2024 |
| RUSSELL INVESTMENT FUNDS | 0.00% | 11,883 | - | - | Dec 31, 2023 |
| EQ ADVISORS TRUST | 0.00% | 207,567 | -10,793 | -4.94% | Dec 31, 2023 |
| iSHARES TRUST | 0.00% | 2,709,856 | - | - | Feb 29, 2024 |
| VANGUARD SCOTTSDALE FUNDS | 0.00% | 313,420 | 39,289 | 14.33% | Feb 29, 2024 |
| RYDEX SERIES FUNDS | 0.00% | 652 | - | - | Dec 31, 2023 |
| Blackstone Alternative Investment Funds | 0.00% | 15,900 | 5,900 | 59.00% | Dec 31, 2023 |
| ProFunds | 0.00% | 1,017 | 417 | 69.50% | Jan 31, 2024 |
| VALIC Co I | 0.00% | 27,388 | -110 | -0.40% | Feb 29, 2024 |
| SPDR SERIES TRUST | 0.00% | 3,367,391 | - | - | Dec 31, 2023 |
| RYDEX DYNAMIC FUNDS | 0.00% | 323 | - | - | Dec 31, 2023 |
| NATIONWIDE VARIABLE INSURANCE TRUST | 0.00% | 10,798 | -37,373 | -77.58% | Dec 31, 2023 |
| NATIONWIDE MUTUAL FUNDS | 0.00% | 8,576 | -76 | -0.88% | Jan 31, 2024 |
| PENN SERIES FUNDS INC | 0.00% | 1,800 | - | - | Dec 29, 2023 |
| PGIM ETF TRUST | 0.00% | 3,761 | - | - | Feb 29, 2024 |
| VANGUARD WELLINGTON FUND | 0.00% | 20,187 | - | - | Feb 29, 2024 |
| Dimensional ETF Trust | 0.00% | 20,529 | - | - | Jan 31, 2024 |
| NORTHERN FUNDS | 0.00% | 41,476 | - | - | Dec 29, 2023 |
| PROSHARES TRUST | 0.00% | 10,457 | -3,203 | -23.45% | Feb 29, 2024 |
| RYDEX VARIABLE TRUST | 0.00% | 43 | - | - | Dec 31, 2023 |
| Invesco Exchange-Traded Self-Indexed Fund Trust | 0.00% | 8,053 | - | - | Feb 29, 2024 |
| MASTER INVESTMENT PORTFOLIO | 0.00% | 3,133 | - | - | Dec 31, 2023 |
| Guggenheim Active Allocation Fund | 0.00% | 219 | - | - | Feb 29, 2024 |
| ALLSPRING MASTER TRUST | 0.00% | 2,244 | - | - | Feb 29, 2024 |
| GMO TRUST | 0.00% | 46,719 | - | - | Feb 29, 2024 |
| LINCOLN VARIABLE INSURANCE PRODUCTS TRUST | 0.00% | 59,700 | - | - | Dec 31, 2023 |
| ALLIANZ VARIABLE INSURANCE PRODUCTS TRUST | 0.00% | 1,356 | - | - | Dec 31, 2023 |
| ADVANCED SERIES TRUST | 0.00% | 102,858 | - | - | Dec 29, 2023 |
| SUNAMERICA SERIES TRUST | 0.00% | 8,085 | -33 | -0.41% | Jan 31, 2024 |
| MORGAN STANLEY PATHWAY FUNDS | 0.00% | 1,957 | - | - | Feb 29, 2024 |
| COLLEGE RETIREMENT EQUITIES FUND | 0.00% | 18,676 | - | - | Dec 31, 2023 |
| VANGUARD WORLD FUND | 0.00% | 3,512 | - | - | Feb 29, 2024 |
| Brighthouse Funds Trust I | 0.00% | 128,150 | - | - | Dec 31, 2023 |
| Brighthouse Funds Trust II | 0.00% | 24,216 | - | - | Dec 31, 2023 |
| SEI INSTITUTIONAL MANAGED TRUST | 0.00% | 30,442 | - | - | Dec 31, 2023 |
| DFA INVESTMENT DIMENSIONS GROUP INC | 0.00% | 9,465 | - | - | Jan 31, 2024 |
| Goldman Sachs Trust II | 0.00% | 52,810 | - | - | Jan 31, 2024 |
| iShares U.S. ETF Trust | 0.00% | 1,030 | - | - | Jan 31, 2024 |
| BLACKROCK FUNDS | 0.00% | 61,112 | - | - | Feb 29, 2024 |
| JOHN HANCOCK VARIABLE INSURANCE TRUST | 0.00% | 17,702 | -994 | -5.32% | Dec 31, 2023 |
| PACIFIC SELECT FUND | 0.00% | 27,659 | -3,015 | -9.83% | Dec 31, 2023 |
| Advisors' Inner Circle Fund III | 0.00% | 114 | - | - | Jan 31, 2024 |
| WILSHIRE MUTUAL FUNDS INC | 0.00% | 1,650 | - | - | Dec 31, 2023 |
| Bridge Builder Trust | 0.00% | 29,756 | - | - | Dec 31, 2023 |
| MASSMUTUAL SELECT FUNDS | 0.00% | 3,026 | - | - | Dec 31, 2023 |
| FIRST TRUST EXCHANGE-TRADED FUND VIII | 0.00% | 256 | - | - | Feb 29, 2024 |
| BlackRock Variable Series Funds, Inc. | 0.00% | 9,437 | - | - | Dec 31, 2023 |
| Fidelity Rutland Square Trust II | 0.00% | 1,600 | 1,600 | - | Feb 29, 2024 |
| SEI INSTITUTIONAL INVESTMENTS TRUST | 0.00% | 7,900 | - | - | Feb 29, 2024 |
| John Hancock Funds II | 0.00% | 4,183 | - | - | Feb 29, 2024 |
Kezar Life Sciences's largest mutual fund holder by % of total assets is "Manager Directed Portfolios", owning 600.08K shares, compromising 3.66% of its total assets.
Kezar Life Sciences Institutional Ownership Trends
Institutional Holdings Trend
| Date | Holdings | Change % |
|---|---|---|
| 31 Mar, 24 | 85 | 3.66% |
| 31 Dec, 23 | 82 | -5.75% |
| 30 Sep, 23 | 87 | -20.91% |
| 30 Jun, 23 | 110 | -21.99% |
| 31 Mar, 23 | 141 | 15.57% |
| 31 Dec, 22 | 122 | -8.96% |
| 30 Sep, 22 | 134 | -1.47% |
| 30 Jun, 22 | 136 | 7.94% |
| 31 Mar, 22 | 126 | 13.51% |
| 31 Dec, 21 | 111 | 42.31% |
| 30 Sep, 21 | 78 | 6.85% |
| 30 Jun, 21 | 73 | -12.05% |
| 31 Mar, 21 | 83 | 10.67% |
| 31 Dec, 20 | 75 | -2.60% |
| 30 Sep, 20 | 77 | -7.23% |
| 30 Jun, 20 | 83 | 43.10% |
| 31 Mar, 20 | 58 | 5.45% |
| 31 Dec, 19 | 55 | 1.85% |
| 30 Sep, 19 | 54 | 3.85% |
| 30 Jun, 19 | 52 | 4.00% |
| 31 Mar, 19 | 50 | 25.00% |
| 31 Dec, 18 | 40 | 8.11% |
| 30 Sep, 18 | 37 | 37.04% |
| 30 Jun, 18 | 27 | - |
As of 31 Mar 24, 85 institutions are holding Kezar Life Sciences's shares, representing an increase of 3.66% compared to the previous quarter.
Shares Outstanding Trend
| Date | Shares Outstanding | Change % |
|---|---|---|
| 31 Mar, 24 | 44,737,705 | -9.25% |
| 31 Dec, 23 | 49,298,586 | -11.06% |
| 30 Sep, 23 | 55,427,679 | -2.39% |
| 30 Jun, 23 | 56,787,539 | -5.14% |
| 31 Mar, 23 | 59,865,758 | 4.58% |
| 31 Dec, 22 | 57,241,950 | -0.20% |
| 30 Sep, 22 | 57,356,408 | 4.80% |
| 30 Jun, 22 | 54,729,438 | 24.32% |
| 31 Mar, 22 | 44,021,334 | 9.42% |
| 31 Dec, 21 | 40,230,125 | 43.31% |
| 30 Sep, 21 | 28,072,732 | 1.55% |
| 30 Jun, 21 | 27,644,039 | 3.18% |
| 31 Mar, 21 | 26,791,485 | 13.90% |
| 31 Dec, 20 | 23,522,454 | 1.56% |
| 30 Sep, 20 | 23,160,974 | 0.26% |
| 30 Jun, 20 | 23,099,925 | 25.00% |
| 31 Mar, 20 | 18,480,372 | 101.45% |
| 31 Dec, 19 | 9,173,566 | -2.67% |
| 30 Sep, 19 | 9,425,080 | -5.84% |
| 30 Jun, 19 | 10,009,511 | 0.95% |
| 31 Mar, 19 | 9,915,074 | 6.18% |
| 31 Dec, 18 | 9,337,661 | 3.13% |
| 30 Sep, 18 | 9,054,019 | 10.92% |
| 30 Jun, 18 | 8,162,306 | - |
Kezar Life Sciences (KZR) has 44.74M shares outstanding as of 31 Mar 24, down -9.25% compared to the previous quarter.
Institutional Ownership Trend
| Date | Ownership % | Change % |
|---|---|---|
| 31 Mar, 24 | 61.66% | 1.34% |
| 31 Dec, 23 | 67.83% | 1.16% |
| 30 Sep, 23 | 76.49% | 1.24% |
| 30 Jun, 23 | 78.51% | 1.15% |
| 31 Mar, 23 | 82.77% | 1.32% |
| 31 Dec, 22 | 79.25% | 1.25% |
| 30 Sep, 22 | 79.49% | 1.10% |
| 30 Jun, 22 | 85.14% | 1.62% |
| 31 Mar, 22 | 72.61% | 1.25% |
| 31 Dec, 21 | 76.25% | 2.62% |
| 30 Sep, 21 | 53.94% | 1.90% |
| 30 Jun, 21 | 53.26% | 1.93% |
| 31 Mar, 21 | 52.47% | 2.38% |
| 31 Dec, 20 | 46.97% | 2.19% |
| 30 Sep, 20 | 46.32% | 1.60% |
| 30 Jun, 20 | 53.80% | 1.70% |
| 31 Mar, 20 | 56.23% | 2.43% |
| 31 Dec, 19 | 48.07% | 1.97% |
| 30 Sep, 19 | 49.36% | 1.79% |
| 30 Jun, 19 | 52.48% | 1.94% |
| 31 Mar, 19 | 52.07% | 2.16% |
| 31 Dec, 18 | 49.13% | 2.16% |
| 30 Sep, 18 | 47.64% | 2.58% |
| 30 Jun, 18 | 42.95% | - |
As of 31 Mar 24, Kezar Life Sciences is held by 61.66% institutional shareholders, representing a 1.34% growth compared to 31 Dec 23.
Institutional Increased Positions Trend
| Date | Increased Positions | Change % |
|---|---|---|
| 31 Mar, 24 | 38 | -5.00% |
| 31 Dec, 23 | 40 | 2.56% |
| 30 Sep, 23 | 39 | -27.78% |
| 30 Jun, 23 | 54 | -34.15% |
| 31 Mar, 23 | 82 | 30.16% |
| 31 Dec, 22 | 63 | -25.88% |
| 30 Sep, 22 | 85 | 7.59% |
| 30 Jun, 22 | 79 | 14.49% |
| 31 Mar, 22 | 69 | -2.82% |
| 31 Dec, 21 | 71 | 82.05% |
| 30 Sep, 21 | 39 | 14.71% |
| 30 Jun, 21 | 34 | -5.56% |
| 31 Mar, 21 | 36 | -7.69% |
| 31 Dec, 20 | 39 | 5.41% |
| 30 Sep, 20 | 37 | -33.93% |
| 30 Jun, 20 | 56 | 40.00% |
| 31 Mar, 20 | 40 | 29.03% |
| 31 Dec, 19 | 31 | -6.06% |
| 30 Sep, 19 | 33 | -13.16% |
| 30 Jun, 19 | 38 | -7.32% |
| 31 Mar, 19 | 41 | 64.00% |
| 31 Dec, 18 | 25 | - |
| 30 Sep, 18 | 25 | -7.41% |
| 30 Jun, 18 | 27 | - |
38 institutional shareholders have increased their position in KZR stock as of 31 Mar 24 compared to 40 in the previous quarter (a -5.00% decrease).
Institutional Reduced Positions Trend
| Date | Reduced Positions | Change % |
|---|---|---|
| 31 Mar, 24 | 27 | 3.85% |
| 31 Dec, 23 | 26 | -16.13% |
| 30 Sep, 23 | 31 | -6.06% |
| 30 Jun, 23 | 33 | -15.38% |
| 31 Mar, 23 | 39 | -4.88% |
| 31 Dec, 22 | 41 | 41.38% |
| 30 Sep, 22 | 29 | -14.71% |
| 30 Jun, 22 | 34 | -17.07% |
| 31 Mar, 22 | 41 | 78.26% |
| 31 Dec, 21 | 23 | - |
| 30 Sep, 21 | 23 | -11.54% |
| 30 Jun, 21 | 26 | -16.13% |
| 31 Mar, 21 | 31 | 34.78% |
| 31 Dec, 20 | 23 | -17.86% |
| 30 Sep, 20 | 28 | 47.37% |
| 30 Jun, 20 | 19 | 18.75% |
| 31 Mar, 20 | 16 | 6.67% |
| 31 Dec, 19 | 15 | 66.67% |
| 30 Sep, 19 | 9 | 12.50% |
| 30 Jun, 19 | 8 | 33.33% |
| 31 Mar, 19 | 6 | -33.33% |
| 31 Dec, 18 | 9 | 12.50% |
| 30 Sep, 18 | 8 | - |
| 30 Jun, 18 | - | - |
27 institutional shareholders have reduced their position in KZR stock as of 31 Mar 24 compared to 26 in the previous quarter (a 3.85% increase).
All Institutional Ownership Trend Data
| Date | Holdings | Change % | Shares Outstanding | Change % | Ownership % | Change % | Increased Positions | Change % | Reduced Positions | Change % |
|---|---|---|---|---|---|---|---|---|---|---|
| 31 Mar, 24 | 85 | 3.66% | 44,737,705 | -9.25% | 61.66% | 1.34% | 38 | -5.00% | 27 | 3.85% |
| 31 Dec, 23 | 82 | -5.75% | 49,298,586 | -11.06% | 67.83% | 1.16% | 40 | 2.56% | 26 | -16.13% |
| 30 Sep, 23 | 87 | -20.91% | 55,427,679 | -2.39% | 76.49% | 1.24% | 39 | -27.78% | 31 | -6.06% |
| 30 Jun, 23 | 110 | -21.99% | 56,787,539 | -5.14% | 78.51% | 1.15% | 54 | -34.15% | 33 | -15.38% |
| 31 Mar, 23 | 141 | 15.57% | 59,865,758 | 4.58% | 82.77% | 1.32% | 82 | 30.16% | 39 | -4.88% |
| 31 Dec, 22 | 122 | -8.96% | 57,241,950 | -0.20% | 79.25% | 1.25% | 63 | -25.88% | 41 | 41.38% |
| 30 Sep, 22 | 134 | -1.47% | 57,356,408 | 4.80% | 79.49% | 1.10% | 85 | 7.59% | 29 | -14.71% |
| 30 Jun, 22 | 136 | 7.94% | 54,729,438 | 24.32% | 85.14% | 1.62% | 79 | 14.49% | 34 | -17.07% |
| 31 Mar, 22 | 126 | 13.51% | 44,021,334 | 9.42% | 72.61% | 1.25% | 69 | -2.82% | 41 | 78.26% |
| 31 Dec, 21 | 111 | 42.31% | 40,230,125 | 43.31% | 76.25% | 2.62% | 71 | 82.05% | 23 | - |
| 30 Sep, 21 | 78 | 6.85% | 28,072,732 | 1.55% | 53.94% | 1.90% | 39 | 14.71% | 23 | -11.54% |
| 30 Jun, 21 | 73 | -12.05% | 27,644,039 | 3.18% | 53.26% | 1.93% | 34 | -5.56% | 26 | -16.13% |
| 31 Mar, 21 | 83 | 10.67% | 26,791,485 | 13.90% | 52.47% | 2.38% | 36 | -7.69% | 31 | 34.78% |
| 31 Dec, 20 | 75 | -2.60% | 23,522,454 | 1.56% | 46.97% | 2.19% | 39 | 5.41% | 23 | -17.86% |
| 30 Sep, 20 | 77 | -7.23% | 23,160,974 | 0.26% | 46.32% | 1.60% | 37 | -33.93% | 28 | 47.37% |
| 30 Jun, 20 | 83 | 43.10% | 23,099,925 | 25.00% | 53.80% | 1.70% | 56 | 40.00% | 19 | 18.75% |
| 31 Mar, 20 | 58 | 5.45% | 18,480,372 | 101.45% | 56.23% | 2.43% | 40 | 29.03% | 16 | 6.67% |
| 31 Dec, 19 | 55 | 1.85% | 9,173,566 | -2.67% | 48.07% | 1.97% | 31 | -6.06% | 15 | 66.67% |
| 30 Sep, 19 | 54 | 3.85% | 9,425,080 | -5.84% | 49.36% | 1.79% | 33 | -13.16% | 9 | 12.50% |
| 30 Jun, 19 | 52 | 4.00% | 10,009,511 | 0.95% | 52.48% | 1.94% | 38 | -7.32% | 8 | 33.33% |
| 31 Mar, 19 | 50 | 25.00% | 9,915,074 | 6.18% | 52.07% | 2.16% | 41 | 64.00% | 6 | -33.33% |
| 31 Dec, 18 | 40 | 8.11% | 9,337,661 | 3.13% | 49.13% | 2.16% | 25 | - | 9 | 12.50% |
| 30 Sep, 18 | 37 | 37.04% | 9,054,019 | 10.92% | 47.64% | 2.58% | 25 | -7.41% | 8 | - |
| 30 Jun, 18 | 27 | - | 8,162,306 | - | 42.95% | - | 27 | - | - | - |
Kezar Life Sciences Insider Shareholders Trades
Open Market Insider Trades
| Date | Name | Relation | Role | Transaction | Buy/Sell | Shares | Price | Value | Shares Held | Source |
|---|
Open Market Insider Buys
| Date | Name | Relation | Role | Transaction | Buy/Sell | Shares | Price | Value | Shares Held | Source |
|---|
Insider Sells
All Insider Owners Trades
The last insider sell of Kezar Life Sciences's stock was made by Schiller Mark C. on Jan 17 2024, selling - shares at - per share (valued at -).
Kezar Life Sciences Insider Ownership Trends
All Insider Trades Trend
| Date | Buy | Sell | Buy/Sell Ratio |
|---|---|---|---|
| Q1 2024 | 2 | 3 | 66.67% |
| Q4 2023 | 1 | - | - |
| Q3 2023 | 34 | 43 | 79.07% |
| Q2 2023 | 6 | - | - |
| Q1 2023 | 5 | 16 | 31.25% |
| Q4 2022 | 1 | 4 | 25.00% |
| Q3 2022 | 1 | - | - |
| Q2 2022 | 8 | - | - |
| Q1 2022 | 6 | 2 | 300.00% |
| Q4 2021 | 2 | 1 | 200.00% |
| Q3 2021 | 3 | 3 | 100.00% |
| Q2 2021 | 8 | - | - |
| Q1 2021 | 5 | - | - |
| Q4 2020 | 1 | 1 | 100.00% |
| Q2 2020 | 9 | - | - |
| Q1 2020 | 10 | 1 | 1000.00% |
| Q4 2019 | 4 | 1 | 400.00% |
| Q3 2019 | 14 | - | - |
| Q2 2019 | 6 | - | - |
| Q1 2019 | 5 | - | - |
2 total buy trades, and 3 total sell trades (buy/sell ratio of 0.67%) were made by Kezar Life Sciences's insiders, as of Q1 2024.
Open Market Insider Trades Trend
| Date | Buy | Sell | Buy/Sell Ratio |
|---|---|---|---|
| Q1 2024 | - | - | - |
| Q4 2023 | - | - | - |
| Q3 2023 | - | - | - |
| Q2 2023 | - | - | - |
| Q1 2023 | - | 16 | - |
| Q4 2022 | - | 3 | - |
| Q3 2022 | - | - | - |
| Q2 2022 | - | - | - |
| Q1 2022 | 1 | 1 | 100.00% |
| Q4 2021 | - | - | - |
| Q3 2021 | - | - | - |
| Q2 2021 | - | - | - |
| Q1 2021 | - | - | - |
| Q4 2020 | - | - | - |
| Q2 2020 | 2 | - | - |
| Q1 2020 | 6 | - | - |
| Q4 2019 | 2 | - | - |
| Q3 2019 | 12 | - | - |
| Q2 2019 | 1 | - | - |
| Q1 2019 | - | - | - |
As of Q1 2024, Insider owners conducted 0 open market buy trades and 0 open market sell trades of Kezar Life Sciences's stocks.
Kezar Life Sciences Peer Ownership
| Ticker | Company |
|---|---|
| SRZN | Surrozen, Inc. |
| MLYS | Mineralys Therapeutics, Inc. |
| DSGN | Design Therapeutics, Inc. |
| NKTX | Nkarta, Inc. |
| FHTX | Foghorn Therapeutics Inc. |
| NGM | NGM Biopharmaceuticals, Inc. |
| KROS | Keros Therapeutics, Inc. |
| KYMR | Kymera Therapeutics, Inc. |
| STOK | Stoke Therapeutics, Inc. |
| IPSC | Century Therapeutics, Inc. |
| HOWL | Werewolf Therapeutics, Inc. |
| NRIX | Nurix Therapeutics, Inc. |
| RVMD | Revolution Medicines, Inc. Warrant |
| CGEM | Cullinan Oncology, Inc. |
| GLUE | Monte Rosa Therapeutics, Inc. |
| STTK | Shattuck Labs, Inc. |
| LRMR | Larimar Therapeutics, Inc. |
| IKNA | Ikena Oncology, Inc. |
| LYEL | Lyell Immunopharma, Inc. |
| BOLT | Bolt Biotherapeutics, Inc. |
KZR Ownership FAQ
Who Owns Kezar Life Sciences?
Kezar Life Sciences is owned by institutional shareholders (61.66%), insiders (14.84%), and public (23.50%). The largest institutional shareholder of Kezar Life Sciences is SUVRETTA CAPITAL MANAGEMENT, LLC (9.88% of total shares) and the top mutual fund owner is Manager Directed Portfolios (3.66% of total shares).
Who are the major institutional shareholders of Kezar Life Sciences?
Kezar Life Sciences's major institutional shareholders are SUVRETTA CAPITAL MANAGEMENT, LLC, AVIDITY PARTNERS MANAGEMENT LP, BLACKROCK INC., VANGUARD GROUP INC, and SPHERA FUNDS MANAGEMENT LTD.. The top five shareholders own together 30.26% of the company's share outstanding.
How many Kezar Life Sciences shareholders are there?
As of Mar 2024, there are 85 institutional shareholders of Kezar Life Sciences.
What percentage of Kezar Life Sciences is owned by SUVRETTA CAPITAL MANAGEMENT, LLC?
SUVRETTA CAPITAL MANAGEMENT, LLC owns 7.17M shares of Kezar Life Sciences, representing 9.88% of the company's total shares outstanding, valued at $6.46M (as of Mar 2024).
What percentage of Kezar Life Sciences is owned by AVIDITY PARTNERS MANAGEMENT LP?
As of Mar 2024, AVIDITY PARTNERS MANAGEMENT LP holds 5.03M shares of Kezar Life Sciences (KZR), compromising 6.93% of the company, valued at $4.53M.
What percentage of Kezar Life Sciences is owned by BLACKROCK INC?
BLACKROCK INC is the third largest holder of Kezar Life Sciences. The company owns 4.62M of the company's shares outstanding (worth $4.16M).